Ranbaxy recalls 30,000 allergy-relief packs

May 2, 2014

Ranbaxy Laboratories began recalling 29,790 blister packs of an over-the-counter allergy-relief medicine in February after the FDA identified unacceptable packaging defects and the recall is ongoing, according to the FDA.

Ranbaxy Laboratories began recalling 29,790 blister packs of an over-the-counter allergy-relief medicine in February after the FDA identified unacceptable packaging defects and the recall is ongoing, according to the FDA.

In its enforcement report for the week of April 30, FDA noted that “an unacceptable level of blister defects have been identified in Loratadine and Pseudoephedrine Sulfate Extended Release Tablets, 10 mg/240 mg.” The lots were #2554936 and #2554938 with an expiration date of September 2015.

The Ranbaxy Ohm Laboratories plant in New Jersey had manufactured the generic drugs, which had been distributed to CVS Pharmacy in Rhode Island, Discount Drug Mart and Kroger Co. in Ohio, McKesson in California, H-E-B in Texas, and Amerisource Bergen and Rite Aid in Pennsylvania.

This is the company’s only plant manufacturing generics for the United States. Ranbaxy plants in India have been banned from supplying generics to the United States.